Jacob Sophie, Héry Michel, Protois Jean-Claude, Rossert Jérôme, Stengel Bénédicte
INSERM Unit 780, 16, avenue Paul Vaillant-Couturier, 94807 Villejuif cedex, France.
J Am Soc Nephrol. 2007 Jan;18(1):274-81. doi: 10.1681/ASN.2006060652. Epub 2006 Nov 29.
It has been suggested that solvent exposure may have a role in the progression of glomerulonephritis (GN) to ESRD, but this has never been tested with an appropriate cohort study design. A total of 338 non-ESRD patients with a first biopsy for primary GN between 1994 and 2001 were included: 194 IgA nephropathies (IgAN), 75 membranous nephropathies (MN), and 69 FSGS. ESRD, defined as an estimated GFR <15 ml/min per 1.73 m2 or dialysis, was registered during a mean follow-up period of 5 yr. Patients' lifelong solvent exposures before and after diagnosis were recorded by interview and assessed by industrial hygienist experts. Cox models were used to estimate adjusted hazard ratios (HR) of ESRD related to exposures. Overall, 15 and 14% of the patients had been exposed at a low and a high level before diagnosis, respectively. Forty-two with IgAN, 12 with MN, and 22 with FSGS reached ESRD. A graded relationship was observed for MN (age- and gender-adjusted HR [95% confidence interval] for low exposure versus none was 3.1 [0.5 to 18.2] and for high exposure versus none was 8.2 [1.9 to 34.7]) and for IgAN (1.6 [0.7 to 3.9] and 2.2 [1.0 to 4.8]) but not for FSGS. Solvent risk was mediated only partly by baseline proteinuria: Adjusted HR for high exposure versus none was 5.5 (1.3 to 23.9) for MN and 1.8 (0.8 to 3.9) for IgAN. In patients with IgAN, there was a trend in increasing HR with exposure duration before and its persistence after diagnosis. These findings support the hypothesized association of solvent exposure with the progression of GN to ESRD. They should prompt clinicians to give greater attention to patients' occupational exposures and possibly to consider professional reclassification.
有人提出,接触溶剂可能在肾小球肾炎(GN)进展为终末期肾病(ESRD)的过程中起作用,但这从未通过适当的队列研究设计进行过验证。纳入了1994年至2001年间首次因原发性GN进行活检的338例非ESRD患者:194例IgA肾病(IgAN)、75例膜性肾病(MN)和69例局灶节段性肾小球硬化(FSGS)。ESRD定义为估计肾小球滤过率(GFR)<15 ml/(min·1.73 m²)或开始透析,在平均5年的随访期内进行记录。通过访谈记录患者诊断前后的终生溶剂接触情况,并由工业卫生专家进行评估。使用Cox模型估计与接触相关的ESRD调整后风险比(HR)。总体而言,分别有15%和14%的患者在诊断前曾有低水平和高水平的接触。42例IgAN、12例MN和22例FSGS患者发展为ESRD。观察到MN(低接触与无接触相比,年龄和性别调整后的HR[95%置信区间]为3.1[0.5至18.2],高接触与无接触相比为8.2[1.9至34.7])和IgAN(1.6[0.7至3.9]和2.2[1.0至4.8])存在分级关系,但FSGS不存在。溶剂风险仅部分由基线蛋白尿介导:MN高接触与无接触相比的调整后HR为5.5(1.3至23.9),IgAN为1.8(0.8至3.9)。在IgAN患者中,诊断前接触持续时间及其诊断后持续性与HR增加呈趋势。这些发现支持了溶剂接触与GN进展为ESRD之间的假设关联。它们应促使临床医生更加关注患者的职业接触,并可能考虑职业重新分类。